XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis by Yulan Yan et al.
RESEARCH ARTICLE
XPD Asp312Asn and Lys751Gln polymorphisms and breast
cancer susceptibility: A meta-analysis
Yulan Yan & Hongjie Liang & Morning Light & Taijie Li &
Yan Deng & Meng Li & Shan Li & Xue Qin
Received: 26 August 2013 /Accepted: 25 September 2013 /Published online: 8 October 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract The association between xeroderma pigmentosum
complementation groupD (XPD ) Asp312Asn and Lys751Gln
gene polymorphisms and breast cancer risk has been widely
reported, but the results were inconsistent. In order to derive a
more precise estimation of the relationship, a meta-analysis
was performed. A comprehensive search strategy was
conducted towards the electronic databases including
Medline, PubMed, Web of Science, Embase, and Chinese
Biomedical Literature Database (Chinese). The association
between the XPD polymorphism and breast cancer risk was
conducted by odds ratios (ORs) and 95% confidence intervals
(95 % CIs). A total of 22 studies with 18,136 cases and 18,351
controls were included in our meta-analysis. Among these, 12
studies with 7,667 cases and 7,480 controls for Asp312Asn
polymorphism and 20 studies with 10,469 cases and 10,871
controls for Lys751Gln polymorphism. With regard to
Asp312Asn polymorphism, no significantly associated was
found with breast cancer risk. However, significant associa-
tion was found between Lys751Gln polymorphism and breast
cancer risk under all genetic models in overall populations (C
vs. A—OR=1.10, 95 % CI=1.04–1.17, P =0.002; CC vs.
AA—OR=1.17, 95 % CI=1.06–1.30, P =0.003; AC vs.
AA—OR=1.06, 95 % CI=1.01–1.12, P =0.032; CC vs.
AC/AA—OR=1.17, 95 % CI=1.04–1.32, P =0.009; CC/AC
vs. AA—OR=1.07, 95 % CI=1.02–1.12, P =0.005). In sub-
group analysis base on ethnicity, significance was found in
Caucasians and mix. The results suggest that XPD
Asp312Asn polymorphism was not associated with breast
cancer. The XPD Lys751Gln polymorphism significantly in-
creased breast cancer risk, especially for Caucasian and mix.
Keywords XPD . Polymorphism . Breast cancer .
Meta-analysis
Introduction
Breast cancer is the most frequently diagnosed and most
prevalent invasive cancers and the leading cause of cancer-
related death among women, accounting for 23 % of total
cancer cases and 14 % of cancer deaths and 30 % of the new
malignant tumors in females over the worldwide, which has
become a major public health challenge [1–3]. In fact, the
incidence of breast cancer is significantly higher in developed
countries than in developing ones, which was the first malig-
nant disease to pose a significant threat to women [4]. But
unfortunately, the pathogenesis and progression of breast can-
cer are still not fully understood. Many studies have conclud-
ed that breast cancer is the cumulative result of multiple
environmental factors and genetic alterations [5, 6]. Previous
studies have suggested that the stimulation of estrogen [7],
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high weight of birth [8], obesity [9], and family history of
breast cancer [10, 11] were associated with increased risk of
breast cancer especially in postmenopausal women. But not
all people exposed to these risk factors are suffering from
breast cancer, which indicated that genetic plays an important
role in the development of breast cancer.
In recent years, several common low-penetrant genes have
been identified as potential breast cancer susceptibility genes
[12]. Xeroderma pigmentosum complementation group D
(XPD ) or called excision repair cross-complimentary group
2 (ERCC2 ) is one of the most important low-penetrant gene,
which is locating at chromosome 19q13.3 and involving in the
nucleotide excision repair (NER) pathway, removes certain
DNA cross-links, ultraviolet photolesions, and bulky chemi-
cal adducts [13, 14]. The Asp312Asn and Lys751Gln have
been identified as the two most common polymorphisms in
the coding region of XPD and the most extensively studied
[15, 16]. The XPD Asp312Asn polymorphism (rs1799793) at
position 312 in exon 10 is characterized by a G to A substi-
tution resulting in aspartic acid (Asp [D]) to asparagine (Asn
[N]) amino acid, whereas the Lys751Gln polymorphism
(rs13181) is at position 751 in exon 23 and characterized by
an A to C substitution causing a lysine (Lys [K]) to glutamine
[Gln (Q)]) amino acid exchange [15, 16]. This polymorphism
and the association of breast cancer risk has been a research
focus in the scientific community and have drawn increasing
attention. There were a number of studies reporting the role of
XPD Asp312Asn and Lys751Gln polymorphisms in breast
cancer risk [17–38], but the results are inconclusive, this may
partially be because of the possible small effect of the poly-
morphism on breast cancer risk and the relatively small sam-
ple size in each of the published studies. In order to derive a
more precise conclusion, we performed this meta-analysis.
Materials and methods
Search strategy
A comprehensive search strategy was conducted towards the
electronic databases including Medline, PubMed, Web of
Science, Embase, and Chinese Biomedical Literature Data-
base (Chinese), with keywords “breast cancer”, “breast neo-
plasm”, “XPD”, “ERCC2”, “polymorphism”, and “variant”
for all studies; there were no limitations to the language of
publications. Reference lists of the selected papers were
screened by hand for potentially relevant articles; review
articles were also examined to find additional eligible studies.
Inclusion and exclusion criteria
Studies were selected if they satisfy the following inclusion
criteria: (a) case–control design; (b) evaluation of the XPD
polymorphism and breast cancer risk; (c) the publications
must offer the sample size, distribution of alleles, genotypes,
or others information for estimating the odds ratio (OR) and
95 % confidence interval (CI); (d) when multiple publications
reported on the same or overlapping data, we used the most
recent or largest population. The exclusion criteria were as
follows: (a) not a case–control study, (b) no usable data
reported, (c) studies contained duplicate data, and (d) case
reports or reviews.
Data extraction
Information was carefully extracted from all eligible publica-
tions independently by two investigators according to the
inclusion criteria mentioned above. If the conflicting evalua-
tions are encountered, an agreement was reached following a
discussion; if an agreement could not be reached, then a third
author was consulted to resolve the debate The following
information were extracted: the name of first author, year of
publication, country of origin, ethnicity, genotyping methods,
source of the control group, and the distribution of genotypes
in case and control groups. We also evaluated whether the
genotype distributions were in Hardy–Weinberg equilibrium.
Statistical analysis
The possible association between the XPD Asp312Asn poly-
morphism and breast cancer risk was evaluated by OR and
95%CI according to allele contrast (A vs. G), homozygote
(AA vs. GG), heterozygote (GA vs. GG), recessive (AA vs.
GA/GG), and dominant (AA/GA vs. GG) models. While the
strength of association between the XPD Lys751Gln poly-
morphism and breast cancer risk was assessed byOR and 95%
CI according to allele contrast (C vs. A), homozygote (CC vs.
AA), heterozygote (CAvs. AA), dominant model (CC/AC vs.
AA), and recessive model (CC vs. AC/AA), respectively.
Subgroup analyses were assessed according to ethnicity. Het-
erogeneity among studies was checked by a chi-square-based
Q statistic test. The effect of heterogeneity was quantified by
using a P value as well as I2 value [39]. An I2 value of <50 %
or P >0.10 suggest no heterogeneity was existed among stud-
ies; ORs were pooled by fixed-effects model (the Mantel–
Haenszel method) [40]. Otherwise, the random-effects model
(DerSimonian and Laird method) [41] was used.
The publication bias was assessed both by Egger's test (P <
0.05 was considered representative of statistically significant
publication bias) [42] and visual observation of funnel plot
[43]. A professional web-based program (http://ihg2.
helmholtz-muenchen.de/cgibin/hw/hwa1.pl) was conducted
to assess the Hardy–Weinberg equilibrium [44] of controls.
At P >0.05, it suggests that controls followed the Hardy–
Weinberg equilibrium (HWE) balance. Sensitivity analysis
was performed to evaluate the stability of the results. A single
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study involved in the meta-analysis was omitted each time to
reflect the influence of the individual dataset to the pooled
ORs [45]. When the Hardy–Weinberg equilibrium disequilib-
rium existed (P <0.05), the sensitivity analysis was also
conducted. All statistical tests were performed with STATA
Software (version 9.2, Stata Corp).
Results
Search results and study characteristics
After being examined carefully according to the inclusion
criteria (Fig. 1), a total of 22 studies [17–38] with 18,136
cases and 18,351 controls were included in our meta-analysis.
Among these, 12 studies with 7,667 cases and 7,480 controls
for Asp312Asn polymorphism (Table 1) were included in our
meta-analysis and 20 studies with 10,469 cases and 10,871
controls for Lys751Gln polymorphism (Table 2) were includ-
ed in our meta-analysis. The genotype distribution in the
controls of all studies was consistent with HWE (all P >0.05).
Meta-analysis results
The main results of this meta-analysis and the heterogeneity
test were shown in Tables 3 and 4. With regard to Asp312Asn
polymorphism, no significant association was found with
breast cancer risk in overall populations (A vs. G—OR=
1.06, 95 % CI=0.95–1.18, P =0.325; AA vs. GG—OR=
1.06, 95 % CI=0.87–1.29, P =0.591 (Fig. 2a); GA vs. GG—
OR=1.07, 95 % CI=0.96–1.20, P =0.223; AAvs. GA/GG—
OR=1.04, 95 % CI=0.87–1.24, P =0.654; AA/GAvs. GG—
OR=1.06, 95 % CI=0.96–1.16, P =0.273). Similarly, there
was no association found with breast cancer risk in subgroup
analysis base on ethnicity (Table 3; homozygote model is only
shown in Fig. 2b).
However, significant association was found between
Lys751Gln polymorphism and breast cancer risk under all
genetic models in overall populations (C vs. A—OR=1.10,
95% CI=1.04–1.17, P =0.002; CC vs. AA—OR=1.17, 95%
CI=1.06–1.30, P =0.003 (Fig. 3a); AC vs. AA—OR=1.06,
95 % CI=1.01–1.12, P =0.032; CC vs. AC/AA—OR=1.17,
95 % CI=1.04–1.32, P =0.009 (Fig. 3b); CC/AC vs. AA—
OR=1.07, 95 % CI=1.02–1.12, P =0.005). In subgroup anal-
ysis base on ethnicity, significance was found in Caucasians
(C vs. A—OR=1.07, 95 % CI=1.01–1.14, P =0.020; CC vs.
AA—OR=1.09, 95 % CI=1.00–1.17, P =0.045; CC vs. AC/
AA—OR=1.19, 95 % CI=1.03–1.38, P =0.021 (Fig. 4b))
and mix (AC vs. AA—OR=1.08, 95 % CI=1.02–1.15, P =
0.015 (Fig.4a); CC/AC vs. AA—OR=1.06, 95 % CI=1.01–
1.11, P =0.018).
Sensitive analysis
Sensitivity analyses were conducted to determine whether
modification of the inclusion criteria of the meta-analysis
affected the final results. The statistical significance of the
results was not change when any single study was omitted,
indicating the stability of our results (data not shown). So,
results of the sensitivity analysis suggest that the data in our
meta-analysis are relatively stable and credible.
Publication bias
Both Funnel plot and Egger's test were performed to access
the publication bias of our meta-analysis. Funnel plot is rela-
tively straightforward to observe whether the publication bias
is presence, and Egger's test was used to provide statistical
evidence of symmetries of the plots. As shown in Fig. 5a
(Asp312Asn polymorphism) and Fig. 5b (Lys751Gln poly-
morphism), the shape of the funnel plot did not show
obvious asymmetry. Similarly, the results of Egger's test
shows no publication bias was found too (all P >0.05,
data not shown).
Heterogeneity analysis
There was a significant heterogeneity found in both
Asp312Asn and Lys751Gln polymorphisms. To examine the
source of heterogeneity, we analyze the dominant model by
ethnicity, source of control (hospital or population based),
genotyping methods (PCR-RFLP or TaqMan or ARMS-
PCR), and sample size (≤400 subjects or >400 subjects). As
a result, ethnicity (P =0.012) but not sample size (P >0.05),
genotyping methods (P >0.05) or source of control (P >0.05)
was found to contribute to substantial heterogeneity.Fig. 1 Flowchart of selection of studies for inclusion in the meta-analysis
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Discussion
Breast cancer is one of the most common malignant tumors
and the leading causes of cancer-related death among females
in the world and it is a threat to women's health. Many
candidate genes have been reported to be involved in breast
cancer susceptibility, such as CYP19 [46], CASP8 [47],
GSM1 [48], hOGG1 [49], and so on. XPD is a DNA-
dependent ATPase/helicase that is associated with the TFIIH
transcription factor complex and plays an important role in
Table 1 Characteristics of case–control studies included in XPD Asp312Asn (G312A) polymorphism and breast cancer risk
First author Year Country Ethnicity Genotyping methods Source of Control Cases Controls
GG GA AA GG GA AA
Hussien 2012 Egypt Caucasian ARMS-PCR HB 12 45 43 25 50 25
Jelonek 2010 Poland Caucasian PCR-RFLP PB 41 59 21 85 123 23
Wang 2010 China Asian PCR-RFLP PB 624 388 220 925 315 193
Crew 2007 USA Mix Taqman PB 415 478 138 490 454 139
Shen 2006 USA Mix Taqman PB 60 80 16 59 64 30
Jorgensen 2007 USA Mix Taqman PB 110 128 22 102 142 29
Debniak 2006 Poland Caucasian PCR-RFLP PB 672 785 269 492 597 173
Mechanic(a) 2006 USA Caucasian PCR-RFLP PB 543 589 130 489 516 128
Mechanic(b) 2006 USA African-American PCR-RFLP PB 564 181 15 517 145 13
Brauch 2004 Germany Caucasian PCR-RFLP PB 347 173 47 276 255 79
Shi 2004 USA Caucasian PCR-RFLP PB 29 32 8 46 27 6
Tang 2002 USA Mix PCR-RFLP PB 52 31 7 74 28 10
PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital based, PB population based
Table 2 Characteristics of case–control studies included in XPD Lys751Gln (A429C) polymorphisms and breast cancer risk
First author Year Country Ethnicity Genotyping methods Source of Control Cases Controls
AA AC CC AA AC CC
Samson 2010 India Asian TaqMan PB 107 102 41 235 214 51
Jelonek 2010 Poland Caucasian PCR-RFLP PB 54 47 22 116 128 29
Wang 2010 China Asian PCR-RFLP PB 1136 81 15 1316 96 21
Syamala 2009 India Asian PCR-RFLP HB 148 161 50 247 98 22
Synowiec 2008 Poland Caucasian PCR-RFLP PB 15 24 4 30 17 1
Rajaraman 2008 USA Caucasian TaqMan PB 342 377 120 428 494 158
Makowska 2007 Poland Caucasian PCR-RFLP PB 16 19 57 26 52 32
Kipikasova 2008 Slovak Caucasian PCR-RFLP PB 43 53 18 46 50 17
Shen 2006 USA Mix Taqman PB 63 66 25 74 57 22
Costa 2007 Portugal Caucasian PCR-RFLP PB 127 125 30 331 260 69
Jorgensen 2007 USA Mix Taqman PB 30 175 104 34 159 125
Debniak 2006 Poland Caucasian PCR-RFLP PB 703 850 277 432 547 162
Onay 2006 Canada Caucasian Taqman PB 146 194 58 165 167 40
Mechanic(a) 2006 USA Caucasian PCR-RFLP PB 525 590 158 445 538 150
Mechanic(b) 2006 USA African-American PCR-RFLP PB 415 295 51 393 246 40
Metsola 2005 Finland Caucasian PCR-RFLP PB 147 238 96 155 237 88
Brauch 2004 Germany Caucasian PCR-RFLP PB 224 265 97 264 292 87
Terry 2004 USA Mix Taqman PB 387 513 153 453 498 151
Shi 2004 USA Caucasian PCR-RFLP PB 30 31 8 38 35 6
Tang 2002 USA Mix PCR-RFLP PB 45 42 16 54 46 21
PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital based, PB population based
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Table 3 Results of meta-analysis
for XPD Asp312Asn (G312A)
polymorphism and breast cancer
risk
OR odds ratio, CI confidence in-
terval, F fixed effects model, R
random effects model
Comparison Population N Test of association Model Test of heterogeneity
OR 95 % CI P P I2
A vs. G Overall 12 1.06 0.95–1.18 0.325 R 0 88.5
Others 6 1.08 0.93–1.25 0.341 R 0 85.3
Caucasians 6 1.04 0.89–1.21 0.645 R 0 89.0
AA vs. GG Overall 12 1.06 0.87–1.29 0.591 R 0 77.3
Others 6 1.03 0.78–1.37 0.820 R 0 70.0
Caucasians 6 1.09 0.80–1.47 0.584 R 0 82.2
GA vs. GG Overall 12 1.07 0.96–1.20 0.223 R 0 85.7
Others 6 1.16 0.99–1.36 0.067 R 0 82.0
Caucasians 6 0.99 0.88–1.13 0.836 R 0 82.2
AA vs. GA / GG Overall 12 1.04 0.87–1.24 0.654 R 0.001 66.5
Others 6 0.97 0.75–1.26 0.821 R 0.025 61.0
Caucasians 6 1.12 0.85–1.49 0.423 R 0.001 74.6
AA / GA vs. GG Overall 12 1.06 0.96–1.16 0.273 R 0 87.9
Others 6 1.11 0.97–1.28 0.142 R 0 84.6
Caucasians 6 1.00 0.89–1.14 0.962 R 0 87.1
Table 4 Results of meta-analysis
for XPD Lys751Gln (A751C)
polymorphisms and breast cancer
risk
OR odds ratio, CI confidence in-
terval, F fixed effects model, R
random effects model
Comparison Population N Test of association Model Test of heterogeneity
OR 95 % CI P P I2
C vs. A Overall 20 1.10 1.04–1.17 0.002 R 0 76.2
Asian 3 1.28 0.87–1.87 0.211 R 0 92.2
Caucasians 12 1.07 1.01–1.14 0.020 R 0.002 63.0
Mix 4 1.04 0.98–1.10 0.166 F 0.207 34,3
African 1 1.09 0.96–1.23 0.200 F 0 0
CC vs. AA Overall 20 1.17 1.06–1.30 0.003 R 0.001 56.8
Asian 3 1.64 0.85–3.25 0.140 R 0.004 81.9
Caucasians 12 1.09 1.00–1.17 0.045 F 0.119 33.9
Mix 4 1.07 0.95–1.21 0.242 F 0.451 0
African 1 1.19 0.80–1.76 0.398 F 0 0
AC vs. AA Overall 20 1.06 1.01–1.12 0.032 R 0 63.8
Asian 3 1.23 0.82–1.86 0.322 R 0 91.1
Caucasians 12 1.01 0.97–1.04 0.751 F 0.187 26.2
Mix 4 1.08 1.02–1.15 0.015 F 0.705 0
African 1 1.08 0.95–1.23 0.254 F 0 0
CC vs. AC/AA Overall 20 1.17 1.04–1.32 0.009 R 0.001 58.0
Asian 3 1.53 0.93–2.52 0.097 R 0.047 67.3
Caucasians 12 1.19 1.03–1.38 0.021 R 0.009 56.0
Mix 4 0.97 0.85–1.12 0.715 F 0.476 0
African 1 1.14 0.76–1.70 0.528 F 0 0
CC/AC vs. AA Overall 20 1.07 1.02–1.12 0.005 R 0 70.1
Asian 3 1.24 0.85–1.80 0.273 R 0 92.3
Caucasians 12 1.02 0.99–1.05 0.285 F 0.120 33.7
Mix 4 1.06 1.01–1.11 0.018 F 0.280 21.8
African 1 1.08 0.96–1.21 0.203 F 0 0
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NER pathway. XPD participates in the opening of the DNA
helix to allow the excision of the DNA fragment containing
the damaged base [50–52]. To date, a number of epidemio-
logical studies have been conducted to evaluate the role of
polymorphism Asp312Asn and Lys751Gln on breast cancer
susceptibility, but the results remained controversial.
In order to derive a more precise estimation of the relation-
ship, we performed this meta-analysis of 22 studies including
18,136 cases and 18,351 controls. Our results suggest that the
XPD Asp312Asn polymorphism is not associated with breast
cancer development, but strong association between XPD
Lys751Gln polymorphism and breast cancer risk was found
in overall populations; in the subgroup analysis base on eth-
nicity, a significant association was also found in Caucasians
and mix suggesting a possible role of ethnic differences in
genetic backgrounds and the environment they lived in.
Heterogeneity plays an important role when performing
meta-analysis; so, finding the source of heterogeneity is very
important for the final result of the meta-analysis. In current
study, an obvious heterogeneity between the study was found
in the overall population. Heterogeneity cannot be explained
by several possible source of heterogeneity such as source of
control (hospital or population based), genotyping methods
(PCR-RFLP or TaqMan or MassARRAY) or sample size
(≤400 subjects or >400 subjects). By conducting meta-
regression, we found that ethnicity was the major source of
high heterogeneity in our meta-analysis, which could be
explained by the race-specific effect of XPD Asp312Asn
polymorphism and Lys751Gln polymorphism on the suscep-
tibility to breast cancer because different countries may have
different genetic backgrounds and life styles. However, eth-
nicity did not explain all heterogeneity in this meta-analysis
Fig. 2 a The forest plot describing the meta-analysis under homozygous
model for the association between XPD Asp312Asn polymorphism and
the risk of breast cancer in overall population (AA vs. GG). b The forest
plot describing the meta-analysis under homozygous model for the asso-
ciation between XPD Asp312Asn polymorphism and the risk of breast
cancer in subgroup analysis base on ethnicity (AA vs. GG)
Fig. 3 a The forest plot describing the meta-analysis under homozygous
model for the association between XPD Lys751Gln polymorphism and
the risk of breast cancer in overall population (CC vs. AA). b The forest
plot describing the meta-analysis under recessive model for the associa-
tion between XPD Lys751Gln polymorphism and the risk of breast
cancer in overall population (CC vs. CA/AA)
1912 Tumor Biol. (2014) 35:1907–1915
and other sources need further investigating. It is possible that
other limitations of the recruited studies may partially contrib-
ute to the observed heterogeneity. For this reason, we
conducted analyses using the random effects model. Publica-
tion bias is another important aspect which may have a neg-
ative effect on meta-analysis. In our meta-analysis, both Fun-
nel plot and Egger's test were used to test the publication bias
of the included studies. As a result, both the shape of the
funnel plot and statistical results show no obvious publication
bias, this suggests that the publication bias have little effect on
the results in our study and the results of our meta-analysis are
relatively stable.
Although comprehensive analysis was performed to show
the association between XPD Asp312Asn and Lys751Gln
polymorphisms and breast cancer risk, there are still some
limitations that should be pointed out. Firstly, the number of
studies and the number of samples included in the meta-
analysis were relatively small. Secondly, the controls were
not uniformly defined. Some studies used controls that were
population-based, while others used hospital-based controls,
which may not be representative of the general population.
Thirdly, in the subgroup analysis, the number of Africans was
relatively small, thus not having enough statistical power to
explore the real association. Finally, our results were based on
Fig. 4 a The forest plot describing the meta-analysis under heterozygote
model for the association betweenXPD Lys751Gln polymorphism and the
risk of breast cancer in subgroup analysis base on ethnicity (CAvs. AA). b
The forest plot describing the meta-analysis under recessive model for the
association between XPD Lys751Gln polymorphism and the risk of breast
cancer in subgroup analysis base on ethnicity (CC vs. CA/AA)
Fig. 5 a Begg funnel plot for publication bias test for the association
between XPD Asp312Asn polymorphism and the risk of breast cancer
under homozygous model (AAvs. GG). Each point represents a separate
study for the indicated association. Log [OR], natural logarithm of OR.
Horizontal line means effect size. b Begg funnel plot for publication bias
test for the association between XPD Lys751Gln polymorphism and the
risk of breast cancer under heterozygote model (CA vs. AA). Each point
represents a separate study for the indicated association. Log [OR],
natural logarithm of OR. Horizontal line means effect size
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unadjusted estimates, while a more precise analysis should be
conducted if individual data were available, which would
allow for the adjustment by other covariants including age,
menopausal status, obesity, environmental factors, and
lifestyle.
Despite the limitations above, our meta-analysis also had
several advantages. Firstly, a meta-analysis of the association
of XPD polymorphism on breast cancer risk is statistically
more powerful than any other single study. Secondly, the
quality of case–control studies included in the meta-analysis
was met our inclusion criteria and was satisfactory; the sensi-
tivity analysis and publication bias analysis indicated the
results of our meta-analysis are stability, credibility, and con-
vincing. Thirdly, strict searching strategy, which combines
computer-assisted with manual search, makes the eligible
studies included as much as possible.
In summary, the results suggest that XPD Asp312Asn
was not associated with breast cancer. While XPD
Lys751Gln polymorphism significantly increased breast
cancer risk, especially for Caucasian and mix. Considering
the limited sample size and ethnicities included in the
meta-analysis, further larger-scaled and well-designed stud-
ies are needed to confirm our results. Moreover, gene–
gene and gene–environment interactions should also be
considered in future analysis.
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